MA43876B1 - Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale - Google Patents

Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale

Info

Publication number
MA43876B1
MA43876B1 MA43876A MA43876A MA43876B1 MA 43876 B1 MA43876 B1 MA 43876B1 MA 43876 A MA43876 A MA 43876A MA 43876 A MA43876 A MA 43876A MA 43876 B1 MA43876 B1 MA 43876B1
Authority
MA
Morocco
Prior art keywords
lysosomal storage
storage diseases
pharmaceutical compositions
uses against
against lysosomal
Prior art date
Application number
MA43876A
Other languages
English (en)
Other versions
MA43876A (fr
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43876(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA43876A publication Critical patent/MA43876A/fr
Publication of MA43876B1 publication Critical patent/MA43876B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le traitement de maladies de surcharge lysosomale (msl) comprenant l'administration d'acétyl-leucine ou d'un sel pharmaceutiquement acceptable de celle-ci.
MA43876A 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale MA43876B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale

Publications (2)

Publication Number Publication Date
MA43876A MA43876A (fr) 2018-08-15
MA43876B1 true MA43876B1 (fr) 2019-04-30

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43876A MA43876B1 (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA055947A MA55947A (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA055947A MA55947A (fr) 2016-08-11 2017-08-11 Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial

Country Status (28)

Country Link
US (4) US11400067B2 (fr)
EP (4) EP3359146B1 (fr)
JP (4) JP7393943B2 (fr)
KR (4) KR20240110078A (fr)
CN (3) CN121360108A (fr)
AU (3) AU2017308864B2 (fr)
CA (1) CA3033557A1 (fr)
CY (2) CY1121345T1 (fr)
DK (2) DK3482754T3 (fr)
ES (2) ES2849566T3 (fr)
HK (1) HK1253282B (fr)
HR (2) HRP20190344T1 (fr)
HU (2) HUE052837T2 (fr)
IL (2) IL314107A (fr)
LT (2) LT3482754T (fr)
MA (2) MA43876B1 (fr)
MD (2) MD3482754T2 (fr)
ME (1) ME03340B (fr)
MX (2) MX384447B (fr)
PL (2) PL3359146T3 (fr)
PT (2) PT3482754T (fr)
RS (2) RS61442B1 (fr)
RU (1) RU2749515C2 (fr)
SG (1) SG11201901048VA (fr)
SI (2) SI3359146T1 (fr)
SM (2) SMT202100050T1 (fr)
TN (1) TN2019000032A1 (fr)
WO (1) WO2018029657A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052837T2 (hu) * 2016-08-11 2021-05-28 Intrabio Ltd Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
KR20250022899A (ko) * 2018-12-06 2025-02-17 인트라바이오 리미티드 아세틸-류신의 중수소화된 유사체
SG11202109512SA (en) 2019-03-02 2021-09-29 Intrabio Ltd Leucine, acetyl leucine, and related analogs for treating disease
EP4650003A3 (fr) 2019-06-28 2026-01-21 IntraBio Ltd Polythérapie avec de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale
WO2022264037A1 (fr) * 2021-06-14 2022-12-22 Intrabio Ltd. Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
WO2001097829A2 (fr) 2000-06-19 2001-12-27 Genzyme Corporation Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (fr) * 2008-03-14 2009-09-17 Irm Llc Composés, compositions et procédés de traitement des maladies et des troubles liés au stockage lysosomal
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
AU2013273473B2 (en) * 2012-06-06 2016-05-26 Consiglio Nazionale Delle Ricerche Allosteric chaperones and uses thereof
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
HUE052837T2 (hu) 2016-08-11 2021-05-28 Intrabio Ltd Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik
BR112019002730A2 (pt) 2016-08-11 2019-05-14 Intrabio Ltd acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa

Also Published As

Publication number Publication date
DK3482754T3 (da) 2021-02-01
US20240197663A1 (en) 2024-06-20
KR20240110078A (ko) 2024-07-12
SG11201901048VA (en) 2019-03-28
ME03340B (fr) 2019-10-20
CY1121345T1 (el) 2020-05-29
EP3359146A1 (fr) 2018-08-15
HUE041914T2 (hu) 2019-06-28
JP7757446B2 (ja) 2025-10-21
JP2024059863A (ja) 2024-05-01
KR102412724B1 (ko) 2022-06-23
ES2716133T3 (es) 2019-06-10
MX2021008432A (es) 2021-08-19
PL3482754T3 (pl) 2021-07-05
LT3359146T (lt) 2019-04-25
WO2018029657A1 (fr) 2018-02-15
AU2017308864B2 (en) 2023-06-01
LT3482754T (lt) 2021-05-10
AU2023202903A1 (en) 2023-05-25
SI3359146T1 (sl) 2019-05-31
JP2019524821A (ja) 2019-09-05
US20190201359A1 (en) 2019-07-04
CY1123844T1 (el) 2022-05-27
EP4342461A2 (fr) 2024-03-27
IL314107A (en) 2024-09-01
US20260027077A1 (en) 2026-01-29
PL3359146T3 (pl) 2019-07-31
EP4342461A3 (fr) 2024-05-29
AU2023202903B2 (en) 2025-03-06
MA55947A (fr) 2022-03-23
MX2019001577A (es) 2019-08-29
PT3482754T (pt) 2021-02-03
US12433863B2 (en) 2025-10-07
RS58478B1 (sr) 2019-04-30
DK3359146T3 (en) 2019-04-08
IL264610B1 (en) 2024-08-01
KR20190039226A (ko) 2019-04-10
CN109843275A (zh) 2019-06-04
RU2019106493A (ru) 2020-09-11
MA43876A (fr) 2018-08-15
MX384447B (es) 2025-03-14
BR112019002719A2 (pt) 2019-05-14
IL264610A (en) 2019-02-28
EP3482754B1 (fr) 2020-12-23
MD3359146T2 (ro) 2019-04-30
CA3033557A1 (fr) 2018-02-15
US11400067B2 (en) 2022-08-02
HRP20190344T1 (hr) 2019-04-19
HK1253282A1 (en) 2019-06-14
TN2019000032A1 (en) 2020-07-15
KR20220154849A (ko) 2022-11-22
AU2025203479A1 (en) 2025-05-29
ES2849566T3 (es) 2021-08-19
KR20220044372A (ko) 2022-04-07
CN121360108A (zh) 2026-01-20
US12433862B2 (en) 2025-10-07
EP3865126A1 (fr) 2021-08-18
JP2025188157A (ja) 2025-12-25
EP3359146B1 (fr) 2019-01-23
RU2021115932A (ru) 2021-06-08
IL264610B2 (en) 2024-12-01
HUE052837T2 (hu) 2021-05-28
PT3359146T (pt) 2019-03-27
HK1253282B (en) 2020-02-07
CN121360107A (zh) 2026-01-20
KR102467953B1 (ko) 2022-11-16
RU2019106493A3 (fr) 2020-10-26
SMT202100050T1 (it) 2021-03-15
RU2749515C2 (ru) 2021-06-11
HRP20210153T1 (hr) 2021-05-28
JP2022050564A (ja) 2022-03-30
SI3482754T1 (sl) 2021-04-30
MD3482754T2 (ro) 2021-05-31
RS61442B1 (sr) 2021-03-31
AU2017308864A1 (en) 2019-02-21
US20220331278A1 (en) 2022-10-20
SMT201900154T1 (it) 2019-05-10
EP3482754A1 (fr) 2019-05-15
JP7393943B2 (ja) 2023-12-07

Similar Documents

Publication Publication Date Title
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
WO2018005519A3 (fr) Associations médicamenteuses pour le traitement du cancer
EA201792591A1 (ru) Фармацевтические препараты
NZ778223A (en) Modified release tablet formulations containing phosphodiesterase inhibitors
EP4613333A3 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de la protéine kinase akt
WO2018234871A3 (fr) Compositions pour administration de médicaments et leurs procédés d'utilisation
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
TN2019000063A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
EP3404020A4 (fr) Dérivé de pyridinol ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique contenant celui-ci utilisé comme principe actif
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
WO2019151964A3 (fr) Formulations de saxagliptine à délitement buccal
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
ZA202200331B (en) Naltrexone formulation